Bifidobacterium longum BL268

High-tech manufacturing process
 

What is Bifidobacterium longum?

Bifidobacterium species are mainly found in the gastrointestinal tract (GIT) and the vagina. Bifidobacterium longum converts sugars in the large intestine into lactic acid and thus helps to regulate the pH of the intestines. Most strains of Bifidobacterium are naturally present in fermented dairy products such as yoghurt and are also abundant in fermented vegetables such as sauerkraut and Kimchi.

Bifidobacterium longum is a versatile probiotic and can survive serious disorders in the intestine. Unlike other probiotics, this probiotic is not affected by gastric acid, bile, pH fluctuations or passage through the gastrointestinal tract. This good bacterium easily attaches itself to the mucous membrane from the intestines to the colon.

Bifidobacterium longum strains are most common in babies and children, because this bacterium is transmitted at birth by the mother and when the child is breastfed. Children who are born by caesarean section or who are not breastfed should not have this important bacterium. Supplementation is strongly recommended in this case because colonisation of B. longum can play an important role in the development of the gastrointestinal tract for the rest of their lives.

Studies have clearly shown that B. longum has a very beneficial effect on the immune system and helps strengthen the body’s defence against harmful pathogens.

In trials with mice infected with influenza, B. longum was shown to improve their symptoms and reduce mortality, as well as reduce inflammation in the lower respiratory tract.

Bifidobacterium longum is an excellent remedy for digestive problems such as lactose intolerance, as it helps break down most of the sugars in the food.

Studies also show that B. Longum helps prevent constipation, reduce inflammation in certain intestinal disorders such as ulcerative colitis and irritable bowel syndrome, prevent high cholesterol levels, and help prevent the development of certain allergies.

 

More information

Why choosing Bifidobacterium longum BL268?

Fermedics’ probiotics are manufactured to the highest standard and based on years of scientific research. Our patented probiotic strains are different from the others since all our probiotics are protected by a patented five-layer microencapsulation technology!

This 5-layer protection also has the following advantages:

  • major logistical advantages
  • probiotic strains also remain more stable in the capsule or sachet
  • no contamination / interaction with the filling system
  • a fluid powder that is easy to encapsulate

In general, only a few % of the probiotics sold can reach the intestines and this is very little. Most of them are dead before they’re consumed and the probiotics that are still alive, are eliminated by more than 60% through the intestinal juices.

 

Tests with probiotics subjected to 5-layer microencapsulation

The 5-layer protection significantly increases the stability and survival of probiotics and has many advantages compared to unprotected probiotics.

The tests clearly show that coated probiotics are resistant to stomach acid, bile salts and other digestive juices, allowing them to reach the intestine intact, which is not the case with unprotected probiotics. Improving the stability and protection against digestive juices of protected probiotics also means that a lower dosage per day is necessary (cost savings) because of the good protection (6 to10 billion bacteria is a good daily dosage).

Stability test shows that coated probiotics remain almost intact (loss of 7 to 8%) after the first 6 months of storage at room temperature, while uncoated probiotics lose nearly 80% of their activity, which is remarkable. Stability test at room temperature for 12 months shows that coated lactic acid bacteria (through patented 5-layer microencapsulation) are much more robust and stable than uncoated bacteria that have already lost much of their activity after 3 months, and after 6 months there is almost no activity, which is absolutely not the case with coated bacteria.

 

Improving storage stability of probiotics

Both uncoated and coated (by patented 5-layer microencapsulation) lactic acid bacteria were stored at 40 °C for four weeks. The result shows that the efficiency of lactic acid bacteria subjected to patented 5-layer microencapsulation is much better (more than 9 log).

 

Properties of Fermedics’ probiotics

More information

Health benefits

  • Alleviating antibiotic resistance
  • Reducing allergies
  • Lowering LDL-cholesterol
  • Reducing lactose intolerance
  • Improving gastrointestinal function
  • Producing vitamin B complex
  • Reducing inflammation in the intestine
  • Reducing ulcerative colitis & IBS
  • Strengthening the immune system
  • Treatment diarrhea caused by antibiotics

Storage condition

  • Transport is in refrigerated conditions. Therefore, it is preferable that the manufacturer of finished products keeps the raw material in refrigerated state until the beginning of production.
  • Frozen probiotics can easily be stored as a raw material for 2 years without having a significant effect on CFU/g. If probiotics are stored in the refrigerator at 4°C – 8°C, the storage time is also substantially better than at room temperature.
  • After production, probiotics in the package should also preferably be stored in the refrigerator between 4°C – 8 °C, as the result is always better for CFU/g.
  • As soon as the finished products leave the company for distribution to wholesalers and retailers, probiotics can be stored at room temperature (+/- 12 months) if the 25°C is not exceeded. This guarantees the consumer a quality product, even if stored at room temperature.
  • Expiry date: 18 months if the preservation conditions are applied as above.

Technical properties

Fermedics offers you on request all technical data of this ingredient, such as Certificate of Analysis (COA) and price quotation.

MOQ (minimum order quantity) 10 kg

Legislation

Bifidobacterium longum belongs to the list of micro-organisms that have obtained Qualified Presumption of Safety (QPS) status, defined by EFSA in Europe (2007) because of their safe use in food (1).

(1) Annex II of Regulation (EU) No 1169/2011

SourceIncubation methodIdentification of microbePotencyFormRecommended daily dosage
Infant faecesDeep-layer liquid state incubation16S rDNA gene sequencing1.0 x 1011 CFU/gPowder6.0 x 109

This probiotic is obtained by a fermentation process, freeze-dried and subjected to a patented five-layer microencapsulation technology to protect and preserve each individual probiotic strain optimally. It is a white to cream-coloured, free-flowing powder with high stability.

Would you like to receive more scientific info about our probiotics?

Yes please

References

  • Chong ES. A potential role of probiotics in colorectal cancer prevention: review of possible mechanisms of action. World J Microbiol Biotechnol. 2014 Feb;30(2):351-74. doi: 10.1007/s11274-013-1499-6.
  • Colecchia A, Vestito A, La Rocca A, Pasqui F, Nikiforaki A, Festi D, 2006. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterologica e Dietologica, 52, 349-358.
  • Mary Hickson. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol. 2011 May; 4(3): 185-197.
  • Messaoudi M, Lalonde R, Violle N, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011 Mar;105(5):755-64. doi: 10.1017/S0007114510004319.
  • Riedel CU, Foata F, Philippe D, Adolfsson O, Eikmanns BJ, Blum S, 2006. Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappa B activation. World Journal of Gastroenterology, 12, 3729-3735.
  • Slavin J. Fiber and probiotics: mechanisms and health benefits. Nutrients. 2013 Apr 22;5(4):1417-35. doi: 10.3390/nu5041417.
  • Young SL, Simon MA, Baird MA, Tannock GW, Bibiloni R, Spencely K, Lane JM, Fitzharris P, Crane J, Town I, Addo-Yobo E, Murray CS, Woodcock A, 2004. Bifidobacterial species differentially affect expression of cell surface markers and cytokines of dendritic cells harvested from cord blood. Clinical and Diagnostic Laboratory Immunology, 11, 686-690.